Updated: EU pharma CEOs earned 46% less than U.S. peers

CEO pay in Europe continues to be a flashpoint given the high unemployment and austerity measures the workaday folk on the continent face. A new analysis shows the CEOs of European drugmakers continue to pull in far less than their U.S. counterparts. The report from Sam Fazeli, a London-based analyst for Bloomberg Industries, found that the median paycheck for the top pharma dogs in Europe last year was $9.3 million, 46% less than the $17.2 million brought home by CEOs of U.S.-based drugmakers. Further, he found that the average pay of $13.7 million for large-cap pharmaceutical companies was significantly less than the $21.9 million paid to the leaders of industrial companies. Report

Editor's Note: This story has been updated to reflect the correct percentage of pay that European CEOs earned compared to their U.S. counterparts.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.